Saturday, February 8, 2020
Program is subject to change
| 7:00 am | Registration and Continental Breakfast |
| 7:50 | Welcome and Overview / Pre-Program Test Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD |
| Session I: Aging, Disease Pathogenesis, and Imaging Moderators: Philip J. Rosenfeld, MD, PhD and Zohar Yehoshua, MD, MHA |
|
| 8:00 | Metabolic Networks and the RPE-Photoreceptor Ecosystem in Aging and Degeneration Philip Luthert, MBBS |
| 8:08 | Deep Learning and Reticular Pseudodrusen Emily Y. Chew, MD |
| 8:16 | Ultrahigh Speed OCTA for Assessing Choricapillaris Flow Impairment James G. Fujimoto, PhD |
| 8:24 | Challenges in Imaging the Choriocapillaris Richard F. Spaide, MD |
| 8:32 | Choriocapillaris Quantification with Phansalkar's Local Thresholding: Do's and Don'ts Zhongdi Chu, PhD |
| 8:40 | Swept Source OCTA Imaging of Choriocapillaris Associated with Drusen in AMD Philip J. Rosenfeld, MD, PhD |
| 8:48 | Choriocapillaris in Intermediate AMD Robyn Guymer, MBBS, PhD, FRANZCO |
| 8:56 | Do Choriocapillaris Flow Deficits Correlate with the Rate and Directionality of GA Growth? Eric M. Moult, BSc |
| 9:04 | Choriocapillaris in Myopia SriniVas R. Sadda, MD |
| 9:12 | Choroidal Vessel Imaging and Quantification Ruikang (Ricky) Wang, PhD |
| 9:20 | Structural OCT Imaging to Differentiate Between PIC, PIC-CNV and Myopic-CNV Xiaoxin Li, MD |
| Session II: Retinal Diseases and Functional Endpoints Moderators: Thomas A. Albini, MD and Jorge A. Fortun, MD |
|
| 9:28 | Retina Trends – A VC’s Perspective Emmett T. Cunningham, Jr., MD, PhD, MPH |
| 9:36 | MacTel2 as a “Serine/Ceramide-Opathy” Martin Friedlander, MD, PhD |
| 9:44 | Epidemiology of Common Retinal Diseases in Retina Practices in the United States Andrew A. Moshfeghi, MD, MBA |
| 9:52 | Functional Imaging of Mitochondria in Retinal Diseases Rishi P. Singh, MD |
| 10:00 | Novel Analytics to Examine Impact of Fluctuations in Retinal Thickness on Visual Outcomes Usha Chakravarthy, MD |
| 10:08 | Integrating Microperimetry into Clinical Trials of Nonexudative AMD Nadia Waheed, MD |
| 10:16 | Rod-and-Cone-Mediated Vision in Eyes with Hyperreflective Foci: An Outcome Measure for Oil Spill Trials? Christine A. Curcio, PhD |
| 10:24 | Normal and Low Luminance Quantitative Contrast Sensitivity: A Novel Functional Endpoint for Rapid Measurement of Spatial Contrast Sensitivity Functions in Dry AMD Karl G. Csaky, MD, PhD |
| Session III: AMD I Moderators: Philip J. Rosenfeld, MD, PhD and Raquel Goldhardt, MD |
|
| 10:32 | Update on Gene Therapy for Complement Inhibition Jay S. Duker, MD |
| 10:40 | Kamuvudines for AMD: The Saga Continues Jayakrishna Ambati, MD |
| 10:48 | Phase 1 Results of a Systemic Antisense Inhibitor of Complement Factor B for Geographic Atrophy Sunil S. Patel, MD, PhD |
| 10:56 | Phase 1 Single and Multiple Dose Safety Study of Anti-High Temperature Requirement A1 (HtrA1) in Geographic Atrophy (GA) Vrinda Hershberger, MD, PhD |
| 11:04 | Update on Elamipretide for the Treatment of AMD Scott W. Cousins, MD |
| 11:12 | Three-Part Talk on Anti-Integrin Therapy with Risuteganib in Dry AMD 1-Pre-Clinical Data Glenn J. Jaffe, MD |
| 2-Phase 2 Study Results Peter K. Kaiser, MD |
|
| 3-Structure/Function Correlations Glenn J. Jaffe, MD |
|
| 11:28 | Update on Brimonidine Intravitreal Implant for Dry AMD Ryan Rich, MD |
| 11:36 | Avacincaptad Pegol, a Novel C5 Inhibitor for the Treatment of Geographic Atrophy Karl G. Csaky, MD, PhD |
| 11:44 | Pegcetacoplan, a Novel C3 Inhibitor for the Treatment of Geographic Atrophy Cedric G. Francois, MD, PhD |
| Session IV: AMD II Moderators: Harry W. Flynn, Jr., MD and Luis J. Haddock, MD |
|
| 11:52 | PROCON Year 2 Results Jeffrey S. Heier, MD |
| 12:00pm | Non-Neovascular Exudative Age Related Macular Degeneration: How to Unmask the Masquerader David Sarraf, MD |
| 12:08 | Update on Stem Cell Therapies for AMD Amir H. Kashani, MD, PhD |
| 12:16 | Retinal Implants: Where Are We Now? Jean-François Korobelnik, MD |
| 12:24 | Advanced Retinal Implants Mark S. Humayun, MD, PhD |
| 12:32 | Lunch |
| Session V: Macular Neovasculation in AMD Moderators: Philip J. Rosenfeld, MD, PhD and Stephan Michels, MD, MBA |
|
| 1:00 | The Importance of MNV Type Classification in the Interpretation of the Results of Clinical Trials Giovanni Staurenghi, MD |
| 1:08 | Detection of Non-Exudative Subclinical MNV in AMD from Structural OCT Scans Using Deep Learning Aaron Y. Lee, MD |
| 1:16 | AI Based Fluid Quantification on Serial OCT Images from a Patient Self-operated Home OCT Device Anat Loewenstein, MD |
| 1:24 | Automated Volumetric Assessment of Subclinical Non-Exudative MNV Using SS-OCTA Luis de Sisternes, PhD |
| 1:32 | Rotational 3D OCTA Giuseppe Querques, MD, PhD |
| Session VI: Polypoidal Choroidal Vasculopathy Moderators: Philip J. Rosenfeld, MD, PhD and Jackie Kovach, MD |
|
| 1:40 | Diagnosis of PCV Using SS-OCTA Hiroko Terasaki, MD, PhD |
| 1:48 | Volume Rendering of OCTA in PCV K. Bailey Freund, MD |
| 1:56 | A Comparison Study of Polypoidal Choroidal Vasculopathy Imaged with ICGA and SS-OCTA Seung-Young Yu, MD |
| 2:04 | Longitudinal Changes in Subclinical PCV Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI |
| Session VII: Treatments for Neovasculation in AMD and ROP Moderators: Thomas A. Albini, MD and Ninel Z. Gregori, MD |
|
| 2:12 | Immunology of Gene Therapy Janet L. Davis, MD |
| 2:20 | Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for Neovascular AMD (OPTIC Trial) David S. Boyer, MD |
| 2:28 | RGX-314 Gene Therapy for wAMD and Diabetic Retinopathy Jeffrey S. Heier, MD |
| 2:36 | Treatment of Newly Diagnosed and Treatment Resistant Neovascular AMD with the Oral CCR3 Inhibitor ALK4290 Michael W. Stewart, MD |
| 2:44 | Results of the Phase I/II SUSHI Study of Intravitreal RBM-007 in Exudative AMD Quan Dong Nguyen, MD, MSc |
| 2:52 | Update on Phase 1b and Phase 2 Studies of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate with Potential for Extended Durability in Wet AMD Diana V. Do, MD |
| 3:00 | Results of the Opthea OPT-302 Phase 2b Study: Combined VEGF-C / VEGF-D Suppression for nvAMD Pravin U. Dugel, MD |
| 3:08 | Phase 2 LADDER Trial Using the Port Delivery System with Ranibizumab: End of Study, Long-term Follow-up Results Carl D. Regillo, MD |
| 3:16 | Faricimab Update Karl G. Csaky, MD, PhD |
| 3:24 | Update on the Safety and Efficacy of Abicipar Pegol Baruch D. Kuppermann, MD, PhD |
| 3:32 | Brolucizumab Update Lawrence J. Singerman, MD |
| 3:40 | Do We Need More VEGF Blockade?- The Rationale for a Clinical Trial Testing High-Dose Aflibercept David M. Brown, MD |
| 3:48 | Update on ROP and Anti-VEGF Clinical Trials Darius M. Moshfeghi, MD |
| Session VIII: Diabetes Moderators: Harry W. Flynn, Jr. MD and Justin H. Townsend, MD |
|
| 3:56 | Effect of Industry Funding on Abstract Bias in the Literature for Intravitreal Pharmacotherapy for Retinal Vascular Disease Jayanth Sridhar, MD |
| 4:04 | DRCR Retina Network Trials and Real World Experience Jennifer Sun, MD |
| 4:12 | Diabetic Retinopathy Severity Score: Friend or Foe? Lee M. Jampol, MD |
| 4:20 | AI-Assisted Approaches for Diabetic Retinopathy Screening Michael S. Ip, MD |
| 4:28 | The Pattern and Density of Retinal Capillary Plexuses from the Fovea to the Periphery Using SS-OCTA Ramin Tadayoni, MD, PhD |
| 4:36 | Wide-field SS-OCTA is Better than FA in Detecting Capillary Dropout, Neovascularization and IRMA in Diabetic Retinopathy Toshinori Murata, MD, PhD |
| 4:44 | Wide-field SS-OCTA in Diabetic Retinopathy Harry W. Flynn, Jr. MD |
| 4:52 | Development of DME in Fellow Eyes from VIVID/VISTA Dilsher Dhoot, MD |
| 5:00 | Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): 2-Year Outcomes of the Phase 3 PANORAMA Study Charles C. Wykoff, MD, PhD |
| Session IX: Diabetes, Uveitis, and Retinal Degenerations Moderator: Philip J. Rosenfeld, MD, PhD and Thomas A. Albini, MD |
|
| 5:08 | Results of a Phase 1 Study Using the Integrin Antagonist THR-687 in Patients with DME Arshad Khanani, MD |
| 5:16 | A Phase 2 Study of OCS-01: An Effective Topical Dexamethasone for DME Pravin U. Dugel, MD |
| 5:24 | Front-line Local Therapies for Uveitis: From Clinical Trials to Practice Steven Yeh, MD |
| 5:32 | Update on Therapeutic Superchoroidal Injection Thomas A. Albini, MD |
| 5:40 | The Expanding Clinical Spectrum of S-Cone Enhanced Disease or NR2E3 Lawrence A. Yannuzzi, MD |
| 5:48 | Treatments and Clinical Trials in Inherited Retinal Degenerations Byron L. Lam, MD |
| 5:56 | Results of a Clinical Trial Investigating N-acetylcysteine in Retinitis Pigmentosa Peter A. Campochiaro, MD |
| 6:04 | Post-Program Test and Closing Remarks |
| 6:10 | Adjourn/Cocktail Reception |